[
  {
    "ts": "2025-11-11T01:16:32+00:00",
    "headline": "Clear Street Raises PT on Beam Therapeutics (BEAM) to $37 Following Q3 Results",
    "summary": "With significant upside potential and hedge fund interest, Beam Therapeutics Inc. (NASDAQ:BEAM) secured a spot on our list of the 15 stocks set to explode in 2026. On November 5, 2025, Clear Street increased its price target on Beam Therapeutics Inc. (NASDAQ:BEAM) from $34 to $37, while maintaining a “Buy” rating. The revised target reflected […]",
    "url": "https://finance.yahoo.com/news/clear-street-raises-pt-beam-011632151.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "c70a8e35-e2d9-32eb-bc26-71bba76dc373",
      "content": {
        "id": "c70a8e35-e2d9-32eb-bc26-71bba76dc373",
        "contentType": "STORY",
        "title": "Clear Street Raises PT on Beam Therapeutics (BEAM) to $37 Following Q3 Results",
        "description": "",
        "summary": "With significant upside potential and hedge fund interest, Beam Therapeutics Inc. (NASDAQ:BEAM) secured a spot on our list of the 15 stocks set to explode in 2026. On November 5, 2025, Clear Street increased its price target on Beam Therapeutics Inc. (NASDAQ:BEAM) from $34 to $37, while maintaining a “Buy” rating. The revised target reflected […]",
        "pubDate": "2025-11-11T01:16:32Z",
        "displayTime": "2025-11-11T01:16:32Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/3b43cd88473669721d3861c507e76c48",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Clear Street Raises PT on Beam Therapeutics (BEAM) to $37 Following Q3 Results",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/M6.I5B4ofmjKzUteY_Asfw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/3b43cd88473669721d3861c507e76c48.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dV33o5Br86PpanGa9ABE0g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/3b43cd88473669721d3861c507e76c48.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/clear-street-raises-pt-beam-011632151.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/clear-street-raises-pt-beam-011632151.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BEAM"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-11T11:12:40+00:00",
    "headline": "Bristol-Myers Squibb (BMY): Assessing Valuation After Improved Profits and Upgraded Revenue Guidance",
    "summary": "Bristol-Myers Squibb (BMY) grabbed investor attention after releasing its third-quarter results, which showed a sharp rise in net income and higher revenue guidance for 2025. The company highlighted strength across its growth portfolio. See our latest analysis for Bristol-Myers Squibb. Bristol-Myers Squibb has seen its share price rebound recently, with a 7.5% return over the past month following upbeat quarterly results and an outlook upgrade. However, the 1-year total shareholder return...",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-bmy-assessing-111240662.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "d25209f9-a29f-3ae4-8b64-7f7bdce5643c",
      "content": {
        "id": "d25209f9-a29f-3ae4-8b64-7f7bdce5643c",
        "contentType": "STORY",
        "title": "Bristol-Myers Squibb (BMY): Assessing Valuation After Improved Profits and Upgraded Revenue Guidance",
        "description": "",
        "summary": "Bristol-Myers Squibb (BMY) grabbed investor attention after releasing its third-quarter results, which showed a sharp rise in net income and higher revenue guidance for 2025. The company highlighted strength across its growth portfolio. See our latest analysis for Bristol-Myers Squibb. Bristol-Myers Squibb has seen its share price rebound recently, with a 7.5% return over the past month following upbeat quarterly results and an outlook upgrade. However, the 1-year total shareholder return...",
        "pubDate": "2025-11-11T11:12:40Z",
        "displayTime": "2025-11-11T11:12:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/isv7n73YBii.eJbbdO3fww--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MRv2ZxXw0SbLt6U2idf4TQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-bmy-assessing-111240662.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-bmy-assessing-111240662.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-11T15:37:00+00:00",
    "headline": "Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y",
    "summary": "EDIT reports narrower Q3 loss, boosts revenues on a Bristol Myers milestone, and advances in vivo gene-editing program with EDIT-401.",
    "url": "https://finance.yahoo.com/news/editas-q3-loss-narrower-expected-153700145.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "ad5faf27-37af-3e02-bb0c-866894813021",
      "content": {
        "id": "ad5faf27-37af-3e02-bb0c-866894813021",
        "contentType": "STORY",
        "title": "Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y",
        "description": "",
        "summary": "EDIT reports narrower Q3 loss, boosts revenues on a Bristol Myers milestone, and advances in vivo gene-editing program with EDIT-401.",
        "pubDate": "2025-11-11T15:37:00Z",
        "displayTime": "2025-11-11T15:37:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/56d1b0639f9b169b5b1e773c99d1da8d",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1PfCTlsobe085hq9kQ39eQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/56d1b0639f9b169b5b1e773c99d1da8d.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CtPCfYhWGdEMh.kVEHgTDw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/56d1b0639f9b169b5b1e773c99d1da8d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/editas-q3-loss-narrower-expected-153700145.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/editas-q3-loss-narrower-expected-153700145.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EDIT"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-11T19:34:44+00:00",
    "headline": "Jim Cramer on Bristol-Myers: “I’m Backing off on It”",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer offered insights on. Answering a caller’s query about the stock, Cramer stated: “I’m backing off on it because I gotta tell you, I’m trying to see some good news in this Cobenfy that I was really all in on and I’m not getting that […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-bristol-myers-m-193444161.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "dbf9a02f-4772-3ce7-a726-0db9810bc0d3",
      "content": {
        "id": "dbf9a02f-4772-3ce7-a726-0db9810bc0d3",
        "contentType": "STORY",
        "title": "Jim Cramer on Bristol-Myers: “I’m Backing off on It”",
        "description": "",
        "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer offered insights on. Answering a caller’s query about the stock, Cramer stated: “I’m backing off on it because I gotta tell you, I’m trying to see some good news in this Cobenfy that I was really all in on and I’m not getting that […]",
        "pubDate": "2025-11-11T19:34:44Z",
        "displayTime": "2025-11-11T19:34:44Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/7b1d6a1350c79cef49b9cb2889204dd6",
          "originalWidth": 1000,
          "originalHeight": 666,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/E2lv2kKRF2jXt8F.V84xVw--~B/aD02NjY7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/7b1d6a1350c79cef49b9cb2889204dd6.cf.webp",
              "width": 1000,
              "height": 666,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BN9PfJYu5RffW4DiInJR2Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/7b1d6a1350c79cef49b9cb2889204dd6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-bristol-myers-m-193444161.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-bristol-myers-m-193444161.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]